|
GALC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63369318073592E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.65600866353088E-12 |
| Normal-vs-Stage2 |
7.45590034156862E-10 |
| Normal-vs-Stage3 |
1.11022302462516E-15 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
3.592200E-01 |
| Stage1-vs-Stage3 |
1.541440E-01 |
| Stage1-vs-Stage4 |
3.357000E-03 |
| Stage2-vs-Stage3 |
6.973800E-02 |
| Stage2-vs-Stage4 |
7.341600E-03 |
| Stage3-vs-Stage4 |
1.684030E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62725388719309E-12 |
| Normal-vs-AfricanAmerican |
3.48100000002738E-06 |
| Normal-vs-Asian |
1.54098955817972E-13 |
| Caucasian-vs-AfricanAmerican |
6.180500E-02 |
| Caucasian-vs-Asian |
7.631200E-01 |
| AfricanAmerican-vs-Asian |
1.842410E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-15 |
| Normal-vs-Female |
1.64568358940187E-12 |
| Male-vs-Female |
1.620980E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.43769498715119E-15 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.64601665630926E-12 |
| Normal-vs-Age(81-100Yrs) |
2.025200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.853400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.843600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.683600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.425000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.300000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.739800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.151800E-04 |
| Classical-VS-Follicular |
1.652240E-01 |
| Classical-VS-Other |
1.712360E-01 |
| Classical-VS-Normal |
1.46771483855446E-13 |
| Tall-VS-Follicular |
1.161390E-04 |
| Tall-VS-Other |
9.920600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.252420E-01 |
| Follicular-VS-Normal |
1.84889881182926E-11 |
| Other-VS-Normal |
2.32969999999222E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
5.828200E-04 |
|
|
